期刊
EXPERT OPINION ON DRUG SAFETY
卷 21, 期 7, 页码 867-872出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14740338.2022.2073349
关键词
Psoriasis; plaque psoriasis; biologics; secukinumab; children; pediatric population
This article provides an extensive review of the safety and efficiency of secukinumab in the treatment of plaque psoriasis in the pediatric population. The available data suggest that secukinumab may be a promising therapy for children with moderate to severe psoriasis, with a favorable safety profile and sustained efficiency in improving quality of life.
Introduction Psoriasis (Ps) is a common chronic, recurrent, immune-mediated, inflammatory skin disease affecting up to 2% of children. It has a well-established impact on patients' quality of life. Moreover, patients with psoriasis exhibit a higher prevalence of comorbidities, including hypertension, diabetes, and inflammatory bowel disease. Secukinumab is a fully human monoclonal IL-17A antibody, which has been approved for use in children with psoriasis. Nevertheless, there are very little data on the safety of this therapy in the pediatric population. Areas covered The aim of this article was to perform an extensive review of available data concerning secukinumab safety and efficiency in the pediatric population used for the treatment of plaque psoriasis. Moreover, special attention was paid to underline the adverse effects of secukinumab. Expert opinion Although there is very little evidence on the long-term safety of secukinumab use in the pediatric population, this therapy may be a promising modality in children with moderate to severe psoriasis. The available data confirm its favorable safety profile with no serious adverse events and unexpected events. Moreover, the clinical trials revealed sustained efficiency with respect to reaching PASI 75 and decreasing impact of the disease on quality of life
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据